作者：
Tracey A,Day [1]
;
Adam,Penn-Nicholson [2]
;
Angelique Kany Kany,Luabeya [2]
;
Andrew,Fiore-Gartland [3]
;
Nelita,Du Plessis [4]
;
Andre G,Loxton [4]
;
Julie,Vergara [1]
;
Tom A,Rolf [1]
;
Tim D,Reid [2]
;
Asma,Toefy [2]
;
Justin,Shenje [2]
;
Hendrik,Geldenhuys [2]
;
Michele,Tameris [2]
;
Simbarashe,Mabwe [2]
;
Nicole,Bilek [2]
;
Linda-Gail,Bekker [5]
;
Andreas,Diacon [6]
;
Gerhard,Walzl [4]
;
Jill,Ashman [1]
;
Aude,Frevol [1]
;
Zachary K,Sagawa [1]
;
Cecilia,Lindestam Arlehamn [7]
;
Alessandro,Sette [7]
;
Steven G,Reed [1]
;
Rhea N,Coler [8]
;
Thomas J,Scriba [2]
;
Mark,Hatherill [9]
;
TBVPX-203 study team
作者单位：
Infectious Disease Research Institute, Seattle, WA, USA.
[1]
South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
[2]
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
[3]
DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
[4]
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
[5]
TASK Applied Sciences, Cape Town, South Africa.
[6]
Center for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.
[7]
Infectious Disease Research Institute, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; PAI Life Sciences, Seattle, WA, USA.
[8]
South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address: mark.hatherill@uct.ac.za.
[9]
主题词
佐剂, 免疫(Adjuvants, Immunologic);青少年(Adolescent);成年人(Adult);抗体, 细菌(Antibodies, Bacterial);抗结核药(Antitubercular Agents);剂量效应关系, 免疫(Dose-Response Relationship, Immunologic);双盲法(Double-Blind Method);女(雌)性(Female);葡糖苷类(Glucosides);人类(Humans);脂质A(Lipid A);男(雄)性(Male);中年人(Middle Aged);结核分枝杆菌(Mycobacterium tuberculosis);复发(Recurrence);二级预防(Secondary Prevention);结核菌苗(Tuberculosis Vaccines);结核, 抗多种药物性(Tuberculosis, Multidrug-Resistant);结核, 肺(Tuberculosis, Pulmonary);青年人(Young Adult)
DOI
10.1016/S2213-2600(20)30319-2
PMID
33306991
发布时间
2021-07-02
换一批
换一批
